Showing 3781-3790 of 6035 results for "".
- ObjectiveEd Joins Microsoft’s AI for Accessibility Program to Develop Braille AI Tutor Platformhttps://modernod.com/news/objectiveed-joins-microsofts-ai-for-accessibility-program-to-develop-braille-ai-tutor-platform/2477020/ObjectiveEd has joined Microsoft Corp.’s AI for Accessibility program to help further its efforts in maximizing educational outcomes for children with disabilities. As a component of ObjectiveEd’s inclusion in the program, Microsoft has awarded ObjectiveEd a grant that will provide ObjectiveEd wi
- New Approach to Slowing Nearsightedness in Children Shows Promisehttps://modernod.com/news/new-approach-to-slowing-nearsightedness-in-children-shows-promise/2477006/Combining two different treatment methods to slow the progression of myopia may deliver better results than either can achieve on their own. A new, 2-year study shows that treating children with eye drops and contact lenses was 28 percent to 38 percent more effective in slowing myopia. The resear
- AAO Honors Leaders in Medical and Surgical Eye Carehttps://modernod.com/news/aao-honors-leaders-in-medical-and-surgical-eye-care/2476997/The American Academy of Ophthalmology is honoring ophthalmologists who have improved eye care for millions worldwide through their commitment to their patients and their profession. The honorees will be recognized during AAO 2019, the 123rd Annual Meeting of the American Academy of Oph
- Study Reports High Sensitivity in Diabetic Retinopathy Screening Using Smartphones and Automated-AI in Primary-Carehttps://modernod.com/news/study-reports-high-sensitivity-in-diabetic-retinopathy-screening-using-smartphones-and-automated-ai-in-primary-care/2476982/Nearly 50% of patients with diabetes fail to get an annual eye examination done even in the US and Europe. In many countries, less than 10% of patients referred to ophthalmologists by their primary-care physicians actually complete a dilated retinal examination. Technology can play a role in empo
- Mynosys Secures $25 Million Investment; Names Rob Thornhill as CEOhttps://modernod.com/news/mynosys-secures-25-million-investment-names-rob-thornhill-as-ceo/2476976/Mynosys Cellular Devices, manufacturer of the Zepto cataract surgery device, announced it finalized a $25 million financing round, led by Decheng Capital, and named veteran ophthalmology industry executive Rob Thornhill as Chief Executive Officer. This financing provides capital to fuel U.
- Kodiak Sciences Announces Presentation of Durability Data from Clinical Development Program of KSI-301 in Wet AMD, DME, and RVO at AAOhttps://modernod.com/news/kodiak-sciences-announces-presentation-of-durability-data-from-clinical-development-program-of-ksi-301-in-wet-amd-dme-and-rvo-at-aao/2476945/Kodiak Sciences announced that Charles C. Wykoff, MD, PhD, will present first-time results at the annual mneeting of the American Academy of Ophthalmology (AAO) to be held in San Francisco. The Retina Subspecialty Day (
- Johnson & Johnson Vision Care Introduces Acuvue RevitaLens Multi-Purpose Disinfecting Solutionhttps://modernod.com/news/johnson-johnson-vision-care-introduces-acuvue-revitalens-multi-purpose-disinfecting-solution/2476925/Johnson & Johnson Vision has unveiled the first extension of the Acuvue brand name beyond contact lenses with the launch of Acuvue RevitaLens Multi-Purpose Disinfecting Solution (MPDS). Acuvue RevitaLens MPDS delivers disinfection and all-day comfort for reusable contact lens wearers. Its dua
- Oyster Point Pharma Expands Executive Leadership Teamhttps://modernod.com/news/oyster-point-pharma-expands-executive-leadership-team/2476896/Oyster Point Pharma announced the appointment of Dan Lochner, MBA, as its Chief Financial Officer, and John Snisarenko, MBA, as Chief Commercial Officer. Mr. Lochner joins Oyster Point Pharma after spending nearly 15 years, most recently as a Managing Director, at Goldman Sachs asset mana
- Novartis Announces Details of TALON Global Clinical Trial in Wet AMD Comparing Brolucizumab vs Aflibercepthttps://modernod.com/news/novartis-announces-details-of-talon-global-clinical-trial-in-wet-amd-comparing-brolucizumab-vs-aflibercept/2476870/In the phase 3b TALON clinical trial, Novartis announced that the two primary endpoints are superiority for brolucizumab in treatment interval duration and noninferiority in change in visual acuity. Secondary endpoints will examine durability and anatomical outcomes, including retinal fluid resol
- Atia Vision Announces Upcoming Presentations Highlighting Modular Presbyopia-Correcting IOL Technologyhttps://modernod.com/news/atia-vision-announces-upcoming-presentations-highlighting-modular-presbyopia-correcting-iol-technology/2476867/Atia Vision announced its technology will be featured in presentations at two ophthalmology conferences this week in Paris, France. The first presentation will be delivered by the company during the Ophthalmology Futures European Forum, a clinician-driven global m